Encompass Health Co. (NYSE:EHC) Receives $100.38 Consensus PT from Analysts

Encompass Health Co. (NYSE:EHC) has received an average recommendation of “Buy” from the ten research firms that are covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $100.38.

Several analysts recently issued reports on EHC shares. Barclays dropped their price objective on shares of Encompass Health from $113.00 to $109.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Royal Bank of Canada lifted their price objective on Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 22nd. Leerink Partners started coverage on Encompass Health in a report on Wednesday, July 10th. They issued an “outperform” rating and a $100.00 target price for the company. Stephens reissued an “overweight” rating and set a $105.00 price target on shares of Encompass Health in a research report on Tuesday, August 6th. Finally, Truist Financial raised their price objective on shares of Encompass Health from $100.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th.

Encompass Health Stock Up 1.6 %

EHC opened at $93.05 on Wednesday. The stock has a market capitalization of $9.36 billion, a price-to-earnings ratio of 25.15, a PEG ratio of 1.42 and a beta of 0.89. Encompass Health has a fifty-two week low of $57.55 and a fifty-two week high of $94.38. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.35 and a current ratio of 1.35. The company has a fifty day moving average of $87.89 and a two-hundred day moving average of $83.49.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Monday, August 5th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.01 by $0.10. The company had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.30 billion. Encompass Health had a return on equity of 17.83% and a net margin of 7.88%. Encompass Health’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.95 EPS. On average, research analysts expect that Encompass Health will post 4.17 earnings per share for the current year.

Encompass Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, October 1st will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date is Tuesday, October 1st. This is an increase from Encompass Health’s previous quarterly dividend of $0.15. Encompass Health’s dividend payout ratio (DPR) is currently 16.22%.

Insider Buying and Selling at Encompass Health

In other news, CFO Douglas E. Coltharp sold 12,260 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total transaction of $1,058,528.40. Following the completion of the sale, the chief financial officer now owns 136,227 shares in the company, valued at $11,761,839.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Encompass Health

A number of hedge funds and other institutional investors have recently bought and sold shares of EHC. Jackson Creek Investment Advisors LLC grew its holdings in Encompass Health by 364.4% in the fourth quarter. Jackson Creek Investment Advisors LLC now owns 13,910 shares of the company’s stock valued at $928,000 after purchasing an additional 10,915 shares during the last quarter. Trillium Asset Management LLC purchased a new position in shares of Encompass Health during the first quarter valued at approximately $4,432,000. TD Asset Management Inc increased its stake in Encompass Health by 16.0% in the first quarter. TD Asset Management Inc now owns 2,283,674 shares of the company’s stock valued at $188,586,000 after purchasing an additional 314,488 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in Encompass Health by 275.7% in the second quarter. Harbor Capital Advisors Inc. now owns 35,799 shares of the company’s stock valued at $3,071,000 after purchasing an additional 26,270 shares during the period. Finally, TimesSquare Capital Management LLC raised its position in shares of Encompass Health by 18.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 1,150,866 shares of the company’s stock worth $76,786,000 after buying an additional 175,975 shares during the period. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.